Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06364176 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of May 2024 to Jun 3, 2024 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of May 2024 to Jun 3, 2024
    • Site details revised
  3. Eligibility criteria expanded, about 2 wordsv2 See this version in full on ClinicalTrials.gov ↗
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF) on modulator therapy. The main question it aims to answer is if treatment with losartan improves response of the CF transmembrane conductance regulator (CFTR) channel to modulator therapy. Participants will be asked take losartan or placebo for twelve weeks and will have changes in sweat chloride levels measured as a marker of CFTR function.
Trial Details
NCT Number NCT06364176
Lead Sponsor University of Kansas Medical Center
Conditions Cystic Fibrosis
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov